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Abstract
PBX1 is a TALE homeodomain transcription factor involved in organogenesis and tumorigenesis. Although it has been
shown that ovarian, breast, and melanoma cancer cells depend on PBX1 for cell growth and survival, the molecular
mechanism of how PBX1 promotes tumorigenesis remains unclear. Here, we applied an integrated approach by
overlapping PBX1 ChIP-chip targets with the PBX1-regulated transcriptome in ovarian cancer cells to identify genes whose
transcription was directly regulated by PBX1. We further determined if PBX1 target genes identified in ovarian cancer cells
were co-overexpressed with PBX1 in carcinoma tissues. By analyzing TCGA gene expression microarray datasets from
ovarian serous carcinomas, we found co-upregulation of PBX1 and a significant number of its direct target genes. Among
the PBX1 target genes, a homeodomain protein MEOX1 whose DNA binding motif was enriched in PBX1-
immunoprecipicated DNA sequences was selected for functional analysis. We demonstrated that MEOX1 protein interacts
with PBX1 protein and inhibition of MEOX1 yields a similar growth inhibitory phenotype as PBX1 suppression. Furthermore,
ectopically expressed MEOX1 functionally rescued the PBX1-withdrawn effect, suggesting MEOX1 mediates the cellular
growth signal of PBX1. These results demonstrate that MEOX1 is a critical target gene and cofactor of PBX1 in ovarian
cancers.
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Introduction
Pre-B-cell leukemia homeobox-1 (PBX1) belongs to the TALE (three-
amino-acid loop extension) family of atypical homeodomain
proteins, whose members are characterized by a three-residue
insertion in the first helix of the homeodomain [1]. PBX1 protein
interacts with other homeodomain-containing nuclear proteins
such as HOX and MEIS to form heterodimeric transcription
complexes. Biochemical studies have demonstrated that PBX1 and
HOX interact through contacts between the PBX1 homeodomain
and a conserved hexapeptide sequence in the HOX protein [2].
X-ray crystallographic studies have further demonstrated that
PBX1-HOXB1 dimerization is mediated by binding of the HOX
hexapeptide to a pocket in PBX1 located between the three-
residue insertion and the third helix of the PBX1 homeodomain
[3]. The heterodimerization of PBX1 and HOX cooperatively
regulates affinity and specificity of their binding to target DNA
sequences [4,5].
Given its critical role in transcriptional regulation, it comes as
no surprise that PBX1 is involved in a variety of biological
processes from cell fate determination during organogenesis to the
development of human cancers [6,7,8]. Expression of PBX1 is
temporally and spatially regulated to control organ development of
spleen, pancreas, kidney, adrenal gland, and skeleton [9,10,11,12],
and is implicated in the development of Mu¨llerian duct that later
develops into the female genital tract [13].
Emerging results have indicated a role of PBX1 in human
cancer. The PBX1-HOX heterodimer complex was found to
contribute to oncogenic activity in breast cancer and melanoma. A
dominant negative PBX1 protein or HOX hexapeptide motif that
disrupted the interaction between PBX1 and HOX was found to
significantly reduce the proliferation of these cancer cells
[14,15,16,17]. Moreover, PBX1 acts as a pioneer factor in breast
cancer, remodeling the chromatin to favor the recruitment of
estrogen receptor alpha (ERa) [18]. PBX1 has also been
demonstrated to be a downstream effector of the Notch signaling
pathway, which is frequently activated in ovarian, cervical, and
certain types of breast carcinomas [8,19,20]. In light of the
potential role of PBX1 in various cancer types, identifying the
PBX1 transcription target genes in cancer cells is critical to
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elucidating its oncogenic mechanisms. In this study, we performed
an integrated analysis to identify genes whose promoters were
occupied by PBX1 protein and whose expression levels were
regulated by PBX1. We have focused on one PBX1 direct target
gene, MEOX1, and demonstrated its involvement in PBX1-
mediated tumor cell growth as well as its direct interaction with
PBX1.
Results
Global mapping of PBX1 binding sites in ovarian cancer
cells
Since PBX1 is a nuclear transcription factor that binds to
specific promoters, we sought to identify PBX1 binding sites in the
human cancer genome using ChIP-chip analysis. An ovarian
cancer cell line, OVCAR3, was selected because this cell line was
previously reported to overexpress PBX1, and was dependent on
PBX1 expression for cellular survival [8]. PBX1-bound DNA
fragments enriched by ChIP were hybridized to a human
promoter array containing 18,028 gene promoters, representing
a total of 24,659 transcripts. IgG was used as a negative control in
a parallel immunoprecipitation. Any positive peaks overlapping
those from the IgG control were excluded from the PBX1 peak
list. Using a false discovery ratio (FDR)#0.2, we identified 2,299
unique promoters that showed significant PBX1 binding signals
(Table S1). The ChIP-chip data were then used to calculate the
PBX1 peak binding distribution across the entire promoter
regions, and we found that PBX1 binding sites occurred
throughout the promoter regions (Fig. 1). We also performed
ChIP-chip to determine the distribution of RNA polymerase II,
H3K4me3, and H3K27me3 in promoter regions (Fig. 1), and
tested their promoter co-occurrence with PBX1 targets. The
results indicated that PBX1 promoter binding co-occurred with all
three tested markers, with PBX1-RNA polymerase II being the
most significant co-occurrence pair (Table S2). There was no
significant co-occurrence between H3K4me3 and H3K27me3,
indicating that these two histone marks bound to the promoters of
a distinct set of genes.
Potential cofactors collaborating with PBX1
By analyzing DNA sequences enriched by PBX1 ChIP, cis-
regulatory cofactors of PBX1 could be identified by scanning DNA
binding motifs of the previously characterized transcription
factors. The web-based application Cistrome was employed for
this analysis (http://cistrome.dfci.harvard.edu/ap/). The canoni-
cal PBX1 binding motif was found to be among the significantly
enriched sequence motifs (Fig. 2 & Table S3). A plot of the
distances between PBX1 binding and its predicted motif revealed a
normal (bell-shaped) distribution (Fig. S1). In addition to the
PBX1 motif, GATA1, FOSL1, and JUNB transcription factor
motifs were significantly enriched, suggesting their potential
involvement with PBX1 in transcription regulation. Furthermore,
the motif of MEIS1 which is a well-known cofactor of PBX1 and
the ‘‘TAATTA’’ motif for both MEOX1 and HOX were also
enriched in the PBX1 ChIPed sequences.
PBX1 directly-regulated transcriptome
Transcription factors can function directly as well as by long-
range or indirect mechanisms; thus, to identify genes whose
transcription was directly regulated by PBX1, we overlapped the
PBX1-regulated transcriptome with the PBX1 ChIP-chip target
genes. The PBX1 transcriptome was identified by comparing
expression microarray data between PBX1 siRNA-treated and
control siRNA-treated OVCAR3 cells. The knockdown efficiency
of PBX1 siRNA was validated by Western blot (Fig. S2). We
identified 2,094 unique genes whose expression levels were
significantly regulated by PBX1 (FDR,0.01). The canonical
signaling pathways enriched in the PBX1 transcriptome include
Wnt signaling, insulin receptor signaling, and caveolar-mediated
endocytosis signaling (Table S4).
Overlapping PBX1 ChIP-chip target genes and the PBX1
transcriptome identified 195 genes that were potential PBX1
direct target genes (Fig. 3A and Table S5). We further analyzed
the distribution of PBX1 ChIP target genes with respect to the
alterations in the transcriptome in OVCAR3 cells treated with
PBX1 siRNA. We were able to show a significant enrichment of
PBX1 ChIP targets only among genes down-regulated after PBX1
siRNA treatment (Fig. 3B). In contrast, PBX1 ChIP targets were
not enriched in up-regulated genes or in genes whose expression
was unchanged (FDR.0.01). To determine potential transcription
co-regulation for the PBX1 target genes, the 195 identified genes
were overlaid with the ChIP datasets containing modified histone
marks (see above). The results demonstrated that the majority
(,70%) of PBX1 target gene promoters also contained H3K4me3
but only ,2% of PBX1 target gene promoters contained
H3K27me3 (Fig. S3 and Column Q in Table S5). Statistical tests
demonstrated that the 195 presumptive PBX1 target genes
significantly co-occurred with H3K4me3 and RNA polymerase
II, but not with H3K7me3 (Table S2). Taken together, these
results indicated that PBX1 was required for active expression of
the target genes and the promoters of its target genes were often
occupied with H3K4me3, a histone mark associated with actively
transcribed genes.
Seven representative candidates, based on their known func-
tions in cancer biology, were selected from the 195 candidate
PBX1 targets for validation using qPCR. The results confirmed
specific binding of PBX1 to the promoters analyzed (Fig. 4A), and
confirmed transcript down-regulation in response to PBX1
knockdown for each of these analyzed genes (Fig. 4B).
To determine if potential PBX1 cofactors identified from the
motif analysis described above co-occur with PBX1 binding in
promoter regions, we performed ChIP-qPCR for GATA1 and
MEOX1 using PCR primers flanking the peak binding sequences
of PBX1. Western blot analysis demonstrated that both transcrip-
tion factors were expressed in OVCAR3 cells (Fig. S4A). ChIP-
qPCR demonstrated that GATA1 bound to all the tested
promoters and MEOX1 was present in 6 of 7 tested promoters
(Student’s t- test, p,0.01; Fig. 4C).
Correlation of PBX1 and target gene expression in
ovarian cancer tissues
To extrapolate the biological significance of the PBX1 target
genes identified in the OVCAR3 cell line with respect to human
cancer tissues, we performed in silico analysis using a publicly
accessible expression microarray dataset [21] to determine if
PBX1 expression was correlated with its target genes in 9 different
types of carcinoma tissues. A total of 86 candidate PBX1 target
genes were identified in the microarray dataset [21], and these
genes were queried in Oncomine. The results demonstrated that
ovarian carcinoma has a high level of PBX1 expression as
compared to the other 8 types of cancers (Fig. 5). Furthermore, 28
of the 86 queried genes were significantly up-regulated in the
ovarian cancers as compared to other carcinomas (p,0.05).
The recently available TCGA ovarian serous cancer dataset
permitted us to perform statistical analysis to determine the co-
upregulation of PBX1 and its target genes in ovarian carcinomas.
Among 195 potential PBX1 target genes, further analysis was
performed on a total of 137 for whom gene expression data were
Pbx1 Direct Target Genes in Ovarian Cancer Cells
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present in all three different microarray platforms available from
the cBio Cancer Genomics Portal (http://www.cbioportal.org/
public-portal/). Among these 137 PBX1 target genes, 53 genes
showed a tendency toward co-upregulation with PBX1 (odds ratio
.1.5), of which 18 (13.1%) were significant (p,0.05). This is
higher than would be expected by chance (p=0.013, Chi-square
test), because applying the same analysis to the entire set of 11,201
genes available for analysis revealed that only 873 (7.8%) genes
showed both an odds ratio greater than 1.5 and p,0.05. The odds
ratio and significance (p-value) of co-upregulation of PBX1 and its
target genes are shown in Table S5 columns H and I, respectively.
MEOX1 directly interacts with PBX1 and rescues the
PBX1-withdrawn effect
We then selected MEOX1, one of the direct targets of PBX1, for
further functional studies. Like PBX1, MEOX1 is a homeodomain
protein and can potentially interact with PBX1 to form
heterodimeric transcription complexes. Thus, we asked if MEOX1
and PBX1 physically interacted in cells. A co-immunoprecipita-
tion experiment was performed in HEK293 cells transfected with
PBX1-V5 and MEOX1-FLAG cDNA expression vectors. The
results demonstrated that PBX1 pull-down using a V5 antibody
significantly enriched MEOX1 protein detected by Western blot
with a FLAG antibody (Fig. 6A). Reciprocal co-immunoprecipi-
tation confirmed that MEOX1 co-immunoprecipitated with
PBX1 (Fig. 6A).
We also tested a panel of PBX1-regulated genes to determine if
MEOX1 was involved in regulating their transcription. Using
MEOX1 siRNA, we found that expression of six of the seven
PBX1-regulated genes was also dependent on MEOX1. In
addition, we found that PBX1 transcription was dependent on
MEOX1, as MEOX1 siRNA decreased the PBX1 mRNA level.
Reciprocally, the MEOX1 mRNA level was down-regulated by
PBX1 knockdown. Previous studies have demonstrated that PBX1
was essential for cell growth in ovarian cancer cells including
OVCAR3; here, we performed siRNA knockdown to determine if
MEOX1 knockdown produced a phenotype similar to PBX1
knockdown. The results demonstrated that MEOX1 knockdown
significantly reduced cell growth in OVCAR3 cells, a phenotype
resembling the PBX1-withdrawn effect (Fig. S5).
To test if MEOX1 mediated the cell growth function of PBX1,
we expressed MEOX1 constitutively (driven by a CMV promoter)
and suppressed PBX1 expression using siRNA. We found that
constitutive MEOX1 expression partially protected cells from
PBX1 withdrawal-induced growth suppression, as significantly
greater cell numbers were observed in MEOX1-transfected cells
compared to control plasmid-transfected cells (Fig. 6B). These
findings suggest that MEOX1 is an essential mediator of the
PBX1-related growth signal, although expression of MEOX1 itself
is not sufficient to stimulate cellular proliferation (Fig. S6).
Discussion
The homeobox gene family, which is critical in transcriptional
regulation, encodes nuclear proteins containing highly conserved
DNA-binding homeodomains [22]. Homeobox proteins are
involved in critical activities during development and tumorigen-
esis. In this report, we focused on one of the homeobox genes,
PBX1, which was found to play a critical role in ovarian cancer,
with the intent of identifying and characterizing its transcriptional
network in cancer cells. Integrating analysis of gene promoters
Figure 1. Distribution of PBX1, RNA polymerase II, H3K4me3, and H3K27me3 binding events at gene promoters. Histograms show the
distribution of the peak binding frequency with respect to their position on promoters (x axis). Binding frequency as shown in the y axis was
determined by the number of peak binding events at specific promoter locations. TSS: transcription start site.
doi:10.1371/journal.pone.0036054.g001
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Figure 2. Transcription factor motifs enriched in ChIP-chip target sequences. Selected examples of transcription factor binding motifs that
are statistically enriched in the PBX1 immunoprecipitated DNA sequences.
doi:10.1371/journal.pone.0036054.g002
Figure 3. PBX1 binds to a specific set of genes and controls their transcription in ovarian cancer. A: Venn diagram of PBX1 ChIP-chip
target genes and PBX1 transcriptome reveal a set of overlapping genes that are direct target genes of PBX1. The full list of the overlapping genes is
shown in Table S5. Experiments were performed in OVCAR3 cells. B: Gene set enrichment analysis was performed to determine if PBX1 ChIP targets
are enriched in the PBX1 transcriptome. Genes down-regulated by PBX1 siRNA are significantly enriched in the PBX1 ChIP target set.
doi:10.1371/journal.pone.0036054.g003
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bound by PBX1 and the PBX1 transcriptome allowed us to
identify genes directly regulated by PBX1.
The robustness of our genome-wide ChIP-chip assay is
evidenced by the observation that the canonical PBX1 motif is
highly enriched in the PBX1 ChIPed sequences. We have
demonstrated that 195 PBX1 ChIP targets significantly over-
lapped with promoter occupancy of RNA polymerase II and
H3K4me3, a histone mark associated with active transcription,
but not with H3K27me3, a histone mark associated with
transcription repression. In addition, we found that ChIP targets
were significantly enriched only among genes whose transcription
is supported by PBX1 (downregulated by PBX1 siRNA) but not
among genes whose transcription is suppressed or not affected by
PBX1. These data taken together support the view that PBX1
primarily serves as a transcriptional activator rather than a
repressor in ovarian cancer cells.
The current study also revealed potential cis-regulatory
cofactors of PBX1, which include GATA1, FOSL1, MEIS1,
JUNB, and a ‘‘TAATTA’’ motif for MEOX1 [23] and HOX [24].
The motifs of these transcription cofactors were significantly
enriched in PBX1-bound sequences, suggesting that these proteins
may work in concert with PBX1 to facilitate transcriptional
regulation. Interestingly, several of these potential PBX1 cofactors,
including BCL6 and MEOX1, were also identified being directly
regulated by PBX1, suggesting an auto-regulatory transcriptional
control of these genes. The current study focused on MEOX1 to
assess its co-binding and co-regulatory activity with PBX1. Further
experiments should be performed to determine if other cofactors
serve as co-regulatory factors with PBX1 in cancer cells.
Another exciting finding in this study is the identification of a
new role of MEOX1 in cancer pathogenesis. Although MEOX1 is
well-established as one of the key transcriptional regulators during
embryonic development, our results demonstrate that MEOX1 is
also involved in cancer development through participating in the
PBX1 transcriptional network. The fact that MEOX1 is co-
upregulated with PBX1 in a subset of ovarian carcinomas (Fig. 5)
suggests that a PBX1-MEOX1 molecular axis is involved in the
transcriptional regulation of these carcinomas. Based on this
Figure 4. Validation of promoters bound by PBX1 and its cofactors. A. Seven genes were chosen from the PBX1 ChIP target gene list, and
occupancy of each promoter by PBX1 was validated by ChIP-qPCR analysis. ChIP was performed using either IgG or anti-PBX1 antibody, and the
immunoprecipitated DNA was subjected to qPCR analysis using primers flanking the peak of the PBX1 bound region. B. Transcriptional regulation of
these target genes by PBX1 or MEOX1 was assessed using siRNA and RT-qPCR analysis. Expression of all seven target genes are significantly down-
regulated by PBX1 siRNA as compared to control siRNA (Student’s t-test, p,0.01). Except for ZHX2, MEOX1 siRNA significantly downregulated
expression of the tested genes (Student’s t-test, p,0.01). C. ChIP-qPCR validation of GATA1 and MEOX1 binding near the PBX1-bound sequences.
ChIP was performed using IgG, anti-GATA1, or anti-MEOX1 antibody and the immunoprecipitated DNA was subjected to qPCR using same primers as
in A. Except for binding of MEOX1 to the ZHX2 promoter, binding of GATA1 or MEOX1 to gene promoters is significantly higher than binding of IgG
to the same promoters (Student’s t-test, p,0.01).
doi:10.1371/journal.pone.0036054.g004
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rationale, we performed a ‘‘rescue’’ assay by ectopically expressing
MEOX1 in cancer cells with PBX1 knockdown. Our result
showing that MEOX1 expression reversed the growth inhibitory
effect of PBX1 knockdown suggests that MEOX1 mediates the
growth-supporting function of PBX1 in ovarian cancer cells. Both
PBX1 and MEOX1 belong to the homeodomain family, whose
members usually interact with other homeodomain proteins to
generate heterodimeric protein complexes that are the functional
mediators of transcriptional regulation. Indeed, our co-immuno-
precipitation experiment demonstrated interaction of PBX1 and
MEOX1 proteins, suggesting that MEOX1 can be a critical
homeodomain cofactor of PBX1. Thus, PBX1 appears to act not
only as an upstream regulator but also as a binding cofactor of
MEOX1. This finding is reminiscent of a previous study showing
that PBX1 and HOXB1 cooperate in regulating HOXB1
expression activity in mouse tissues [25]. It can be envisioned
that this positive auto-regulatory loop operates to ensure sustained
transcriptional activity of other PBX1 regulated genes.
The results as reported here represent a first step toward
understanding the complex regulatory network of PBX1 in
carcinomas. As the role of PBX1 in human solid tumors is
emerging, the target genes directly controlled by PBX1 reported
herein will serve as footsteps for deciphering how PBX1
contributes to tumor development. This study also raises several
important questions yet to be addressed. For example, it would be
interesting to test whether the PBX1 regulated genes identified in
ovarian carcinoma are shared with the machinery operating
during organ development. Since overexpression of PBX1 and
MEOX1 is relatively specific to ovarian cancer as compared to
other solid tumors (Fig. 5), the biological significance of PBX1 and
MEOX1 co-expression and their cooperation in transcriptional
regulation are likely to be context- and tissue-dependent. From this
perspective, it would be important to determine if MEOX1
modulates the selectivity and target sequence binding affinity of
the PBX1 transcription complex in ovarian cancer, and ultimately,
it would be interesting to determine how PBX1/MEOX1 complex
formation promotes oncogenesis.
Materials and Methods
Cell Lines
The cell lines used in this study included an ovarian cancer cell
line, OVCAR3, and an embryonic kidney epithelial cell line,
HEK293. Both cell lines were purchased from the American Type
Culture Collection (ATCC, Manassas, Virginia). The cell lines
were maintained in RPMI1640 supplemented with 5% fetal
bovine serum and antibiotics. There was no evidence of
mycoplasma contamination based on a PCR assay.
Chromatin Immunoprecipitation (ChIP) Analysis
For each immunoprecipitation, approximately 126106 OV-
CAR3 cells were used. Cells were plated in 150 mm dishes and
cultured until 80% confluent. Cells were fixed by the addition of
formaldehyde (1% final concentration) to culture media and
incubation for 10 min. The reaction was quenched with 125 mM
glycine for 5 min. Cells were washed in DPBS, nuclei were swollen
in nuclei swelling buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5%
NP 40), and lysed in nuclei lysis buffer (1% SDS, 10 mM EDTA,
Figure 5. PBX1 and several of its direct target genes are over-expressed in ovarian cancer tissues. Oncomine meta-analysis was
performed on a previously published gene expression microarray dataset containing nine different tumor types. Genes were ranked according to
their over-expression in ovarian cancer and the top 18 genes were plotted.
doi:10.1371/journal.pone.0036054.g005
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50 mM Tris-HCl, pH 8.0). Lysed nuclei were sonicated in a
Fisher model 100 sonicator for 5 cycles of 40 sec constant pulse
with 2 min ice incubation in between pulses. Sonicated lysates
were diluted in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-
100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl)
and incubated with Protein G Sepharose (Invitrogen) for 1 hr.
Beads were removed, and bead cleared lysates were incubated
with antibodies against PBX1, GATA1, or MEOX1 (Santa Cruz
sc-899, sc-2656, and Epitomics T2204, respectively) overnight
with rotation at 4uC. A 1:1 slurry of BSA-blocked Protein G
Sepharose was added to antibody incubated lysates and rotated at
4uC for 2–3 hours. Antibody-protein complexes bound to beads
were washed once with Low Salt buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl),
once with LiCl buffer (0.25 M LiCl, 1% NP 40, 1% Sodium
Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and
twice with TE, pH 8.0. Complexes were eluted from beads by
incubating in 1% SDS, 0.1 M NaHCO3 (heated to 65uC) for
30 min at 37uC with shaking. Samples were treated with 200 mM
NaCl and 1 mg RNase A at 65uC overnight. After 1 hr proteinase
K treatment at 37uC, DNA was purified using the Qiagen
QIAquick PCR purification kit and eluted in 100 ml TE.
For qPCR analysis, 2.5 ml of sample was used per reaction.
PCR was performed using SyBr Green dye and an iCycler (Bio-
Rad, Hercules, CA). The threshold cycle numbers (Ct) were
obtained using the iCycler Optical system interface software. PCR
primers were designed using the Primer 3 program (nucleotide
sequences of the primers are shown in Table S6). Data were
normalized using a standard curve, which was prepared from
sonicated input (total) DNA.
ChIP-chip Array Analysis
For ChIP-chip array analysis, ChIP was performed as described
above except for the DNA purification step. DNA was purified
using the Qiagen MinElute PCR purification kit and eluted with
10 ml H2O. The entire immunoprecipitated DNA sample was
amplified using a WGA2 kit (Sigma) and purified using the Qiagen
QIAquick PCR purification kit with an elution volume of 40 ml in
H2O. For input DNA, 200 ng of purified DNA were used for
WGA2 PCR. An aliquot of each amplified sample was diluted to
5 ng/ml and used for qPCR. If 4 mg of DNA were not produced
from the WGA2 PCR, 10 ng of the WGA2 reaction were
reamplified using the WGA3 kit (Sigma), and tested with control
primers again. Aliquots of each sample (4 mg) were sent to
Figure 6. MEOX1 interacts with PBX1 and mediates its growth effect. A. HEK293 cells were transfected with PBX1-V5 and/or MEOX1-FLAG
expression vectors. Immunoprecipitation and Western blot were performed using epitope tag-specific antibodies. B. Left panel: OVCAR3 cells were
transfected with MEOX1 expression vector or control vector. Western blot was performed to test MEOX1 expression (top). The same cells were
transfected with PBX1 siRNA or control siRNA and Western blot was performed to test the down-regulation of PBX1 protein (middle). Detection of
GAPDH protein was used as a loading control (bottom). Right panel: Relative cell numbers were measured in OVCAR3 cells transfected with MEOX1
cDNA, PBX1 siRNA, control plasmid (pLPC), and control siRNA (siLuc). Student’s t-test was used to determine the significance between the MEOX1
over-expressed group and the control group.
doi:10.1371/journal.pone.0036054.g006
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NimbleGen for labeling and array hybridization. The NimbleGen
385K RefSeq promoter 1-plex array was used for sample
hybridization.
For array analysis, the NimbleGen program Signal Map was
used to obtain signal peaks for each sample and to map these peaks
to their corresponding genomic regions. Using the Bioconductor
package GenomicRanges (available at bioconductor.org), we
screened the peak regions from target ChIP-chip with FDR#0.2
for overlap with peaks from non-specific IgG ChIP-chip and
discarded those peaks with at least one bp overlap. The remaining
peaks from target ChIP-chip were considered positive for protein
binding.
Motif search analyses were performed using the seqpos motif
discovery tool (Cistrome, http://cistrome.org/ap/root) and the
TRANSFAC motif database with the following parameter: width
from the peak to be scanned= 600 bp; p,0.05 was set as the cutoff
for significance.
Gene Expression Array Analysis
RNA was isolated from OVCAR3 cells that were previously
treated with either PBX1 siRNA or control siRNA targeting
luciferase gene. RNA labeling, hybridization to the Illumina
human HT-12 Expression Array, and normalization analysis were
performed by the Lowe Family Genomics Core facility, Johns
Hopkins Bayview Medical Center. The fold change of expression
level of each gene was calculated as the ratio of PBX1 siRNA
treatment to control. As there was only one array at each time
point, we used the logarithm of fold change as the test statistic, and
conducted significance analysis to calculate the p-value, which was
defined as the probability of obtaining a test statistic at least as
extreme as the one actually observed under the null hypothesis.
For null distribution we assumed the test statistic followed a
normal distribution where the mean and standard deviation were
estimated from the control samples. We also implemented
Benjamini and Hochberg’s procedure [26] for multiple hypothesis
testing, and estimated the false discovery rate (FDR) for
significantly expressed genes. Significantly up-regulated and
down-regulated genes were finally determined by a predefined
FDR cutoff,0.01.
Statistical test for gene overlapping among array
datasets
To evaluate the significance of overlap between datasets (i.e.
between ChIP-chips and between 195 target genes and ChIP-
chip), we determined the probability of obtaining the same
number or more overlapping genes by randomly sampling from
the full set of genes. The number of genes in the full set was 18,511
for ChIP-chip and 30,500 for expression array. The p-value was
calculated by determining the upper tail probabilities of the
corresponding hypergeometric distribution using phyper() function
in R version 2.14.1.
Statistical test for co-expression between PBX1 and its
target genes
The Z-scores of mRNA expression data from the TCGA
ovarian cancer study were retrieved from the Cancer Genomics
Data Server (CGDS) hosted by Memorial-Sloan-Kettering Cancer
Center (http://www.cbioportal.org/) using the CGDS-R 1.1.19
package (http://cran.r-project.org/web/packages/cgdsr/index.
html). The Z-scores were calculated using diploid tumors (diploid
for each gene) as the reference population, and only genes
represented by all three expression platforms used in the TCGA
study were included [27]. A total of 11,202 genes from 316 tumor
samples with Z-scores were retrieved for analysis.
Over-expression for each gene was defined by a Z-score.1.65
(representing the top 5% in mRNA expression). The tendency of co-
overexpression of PBX1 and its target genes in the same sample was
assessed in the 316 tumor sample set, and odds ratios (ORs) were
calculated. Following the criteria used for co-overexpression test on
cBio Cancer Genomics Portal (http://www.cbioportal.org/), we
considered two genes to have a tendency toward co-overexpression
if their odds ratio was greater than 1.5. The significance of co-
overexpression was further tested using a one-sided Fisher’s exact
test.
Gene knockdown and Quantitative Real-time PCR
PBX1-specific small interfering RNAs (siRNAs) (CCCAG-
GUAUCAAACUGGUUUGGAAA) and (AAGCCUGCCUU-
GUUUAAUGUG) and control siRNA targeting the luciferase
gene (UAAGGCUAUGAAGAGAUA) were purchased from
Invitrogen or synthesized by Integrated DNA Technologies
(Coralville, IA). MEOX1-specific siRNAs were purchased from
Invitrogen (CCAGGAGGAGCACAUCUUCACUGAG and CA-
CUGCCAAUGAGACAGAGAAGAAA). Cells were treated with
siRNA at a final concentration of 100 nM using Lipofectamine
RNAiMax according to the manufacturer’s suggestion (Invitrogen,
Carlsbad, CA). Forty-eight hours after transfection, cells were
harvested for RNA isolation using a Qiagen RNeasy kit. cDNA
was synthesized using 500 ng RNA according to the iScript cDNA
Synthesis kit (Biorad). The cDNA was diluted to a final
concentration of 200 ng/ml, and 1 ml was used for each qRT-
PCR reaction. Relative gene expression was measured by
quantitative real-time PCR using SyBr Green dye and an iCycler
(Bio-Rad). The iCycler Optical system software was employed to
determine the threshold cycle numbers (Ct). PCR primers were
designed using the Vector NTI program (nucleotide sequences of
the primers are shown in Table S7). Mean Ct of the gene of
interest was calculated from duplicate measurements of at least
three separate samples, and was normalized with the mean Ct of a
control gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), for which expression is relatively constant.
In silico analysis of PBX1 gene expression among
different tumor types
In order to assess the correlation of expression levels in PBX1
and its downstream targeted genes in different major types of
human cancer, we performed an in silico analysis using Oncomine,
which provided cancer microarray databases and integrated data-
mining platform [28]. Genes identified as PBX1 targets by ChIP-
chip and microarrays were queried in Oncomine to identify
associated gene expression signatures with the following threshold:
OR=2 and p-value,1024. Associated signatures were filtered for
studies including different cancer types. A heat map was generated
where rank indicates the genes with the highest association with a
particular cancer according to p-value based on t-test. Specifically,
we compared differential gene expression (fold changes) between
ovarian cancer and other cancer types.
Co-Immunoprecipitation and Western Blotting
The generation of a PBX1-V5 expression vector was previously
described [8]. The MEOX1-FLAG expression vector was created
by subcloning the MEOX1 cDNA (Ultimate ORF clone ID:
IOH40231, Invitrogen) into the pLPC-N-FLAG destination
plasmid using the Gateway LR Clonase II enzyme mix following
the manufacturer’s protocol (Invitrogen). Expression plasmids
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were transfected into HEK293 cells using Lipofectamine 2000
(Invitrogen) and 24 h after transfection, cells were harvested for
co-immunoprecipitation experiments. For this, cells were lysed in
lysis buffer (50 mM Tris, ph 8.0, 150 mM NaCl, 1% NP40
supplemented with protease inhibitor cocktail (Thermo Scientific)).
Lysates were then incubated with either anti-V5 agarose (Sigma,
St. Louis, MO), or anti-FLAG M2 affinity gel (Sigma, St. Louis,
MO). After five washes (3 times with lysis buffer and 2 times with
TBS), precipitates were resuspended in Laemmli sample buffer
containing 5% b-mercaptoethanol. Samples were separated by
SDS-PAGE, and transferred onto a PVDF membrane using a
semi-dry transfer apparatus (Bio-Rad). The membrane was
blocked with 5% non-fat dry milk in TBST (20 mM Tris-HCl,
0.5 M NaCl, 0.1% Tween 20) and incubated with a primary
antibody, followed by washes with TBST. Subsequently the
membrane was incubated with horseradish peroxidase-conjugated
secondary antibody (Jackson Laboratories, West Grove, PA) and
detected with ECL developing solution (Thermo Scientific).
Western blot was performed using an anti-FLAG antibody (Sigma,
St. Louis, MO) to detect MEOX1 protein or an anti-V5 antibody
(Bethyl, Montgomery, TX) to detect PBX1 protein. To assure
equal loading of proteins from cellular extracts we probed
membranes with a rabbit polyclonal anti-GAPDH antibody
(Sigma).
Cellular Growth Assay
MEOX1-expressing retrovirus was generated by transfecting
MEOX1-pLPC-N-FLAG plasmid into the Phoenix amphotropic
packaging cell line (gift from Dr. Garry P. Nolan, Stanford
University, CA) as previously described [8]. Viral stock with empty
vector (pLPC-N-FLAG) was also generated to serve as control. For
retroviral transduction, OVCAR3 cells were seeded into 25-cm2
tissue culture flasks and cultured for 24 h prior to infection. Cells
were incubated with 4 ml of viral stock overnight in the presence
of 8 mg/ml polybrene. Viral supernatant was removed and cells
were incubated in regular growth media containing 3 mg/ml
puromycin to establish stable clones. Cells stably expressing
MEOX1 or empty plasmid (pLPC) were transfected with PBX1
specific siRNA or control siRNA using the RNAiMAX transfec-
tion reagent (Invitrogen) according to the manufacturer’s protocol.
Cells were plated in 96-well plates at 56103 cells/well 24 h after
transfection. The cell number was determined 48 h after plating
based on the fluorescence intensity of SYBR green I nucleic acid
staining (Molecular Probes, Eugene, OR) measured in a fluores-
cence microplate reader (Fluostar from BMG, Durham, NC). The
data were expressed as mean 6 SD from triplicate values.
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